KALV
KalVista Pharmaceuticals, Inc.
KalVista Pharmaceuticals, Inc. (KALV) has 14 SEC Form 4 filings (23 transaction rows) in the rolling window, disclosed by 5 distinct insiders. Most recent filing: Jun 11, 2026.
The most active filer is CHIEF DEVELOPMENT OFFICER Yea Christopher with 3 filings. Insiders have net sold $1.6M over the trailing 6 months.
- Industry:Biotechnology
- CEO:Benjamin L. Palleiko
- Employees:275
- HQ:Framingham, MA, US
- IPO:2015-04-09
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$1.6M
reported sales (SEC code S)
Unique Insiders
5
in the rolling window
| Source | ||||||
|---|---|---|---|---|---|---|
| CHIEF DEVELOPMENT OFFICER | Sale | 33,800 | $905K | May 29 | SEC ↗ | |
| CHIEF DEVELOPMENT OFFICER | Sale | 1,966 | $53K | May 27 | SEC ↗ | |
| Chief Commercial Officer | Sale | 1,489 | $40K | May 27 | SEC ↗ | |
| CHIEF MEDICAL OFFICER | Sale | 2,239 | $60K | May 27 | SEC ↗ | |
Palleiko Benjamin LFirst filing | CHIEF EXECUTIVE OFFICER | Sale | 10,926 | $293K | May 26 | SEC ↗ |
Sweeny NicoleFirst filing | Chief Commercial Officer | Sale | 1,861 | $50K | May 26 | SEC ↗ |
Yea ChristopherFirst filing | CHIEF DEVELOPMENT OFFICER | Sale | 2,358 | $63K | May 26 | SEC ↗ |
Audhya Paul K.First filing | CHIEF MEDICAL OFFICER | Sale | 2,685 | $72K | May 26 | SEC ↗ |
Piekos BrianFirst filing | Chief Financial Officer | Sale | 1,489 | $40K | May 26 | SEC ↗ |
Related companies
KalVista Pharmaceuticals, Inc. is in the Healthcare sector.